Business
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium; October 21, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced its intention to wind down its cell therapy business and pursue new transformational business development transactions with its available cash resources. The intention to wind d
About this update from Lakefront Biotherapeutics
[{"type":"image","alt":"Galapagos NV","displaySize":"","headline":null,"caption":"Galapagos NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/231a79f212c8051361274fdd509bada9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n2iAy9u_uXZxYevnIzv00A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/231a79f212c8051361274fdd509bada9","width":300,"height":55}},"lazy":false},{"type":"text","content":"Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos","length":174,"tagName":"p"},{"type":"text","content":"Mechelen, Belgium; October 21, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced its intention to wind down its cell therapy business and pursue new transformational business development transactions with its available cash resources. The intention to wind down follows a comprehensive review of strategic alternatives, including a potential divestiture.","length":425,"tagName":"p"},{"type":"text","content":"The plan would enable the Company to enhance operational efficiencies and focus on utilizing its available cash to execute its strategy of building a pipeline of novel therapeutics through strategic business development transactions under the leadership of its new management team.","length":281,"tagName":"p"},{"type":"text","content":"“We have undertaken a thorough strategic review and sale process to identify potential buyers or investors with the expertise and resources to take the cell therapy business forward,” said Henry Gosebruch, Chief Executive Officer of Galapagos. “Following a limited number of non-binding offers, ultimately no viable proposals were received with terms or financing that would reasonably support the business’ future. After a comprehensive review of all strategic alternatives, given the ongoing investment requirements, coupled with evolving market dynamics and taking into account the interest of all relevant stakeholders, we believe that allocating our capital to other areas of unmet need would be a more attractive use of our resources. Now that this comprehensive strategic review process has concluded,...